|
|
|
|
Document Preview Purchase Agreement |
|
|
|
|
|
Click "Add to Cart" button to purchase document. |
|
|
|
|
|
Title: |
Purchase Agreement |
|
Entities: |
Amgen, Inc.; J.P. Morgan Securities Inc.; Regeneron Pharmaceuticals Inc.; Robertson Stephens, Inc.; Merrill Lynch & Co., Inc.; Latham & Watkins; Shearman & Sterling; Skadden, Arps, Slate, Meagher & Flom LLP |
|
Date: |
2001 |
|
Size: |
Preview shows 25KB of 147KB total |
|
Price: |
$39 |
|
ID: |
#328084 |
|
|
|
|
|
|
|
Start of Preview |
|
REGENERON PHARMACEUTICALS, INC.
(a New York corporation)
7,000,000 Shares of Common Stock
PURCHASE AGREEMENT
Dated: March 19, 2001
================================================================================
{PAGE}
Table of Contents
{TABLE}
{CAPTION}
Page
{S} {C}
SECTION 1. Representations and Warranties.................................................................... 3
-----------------------------------------
(a) Representations and Warranties by the Company.............................................. 3
--- ---------------------------------------------
(i) Compliance with Registration Requirements......................................... 3
--- -----------------------------------------
(ii) Incorporated Documents............................................................ 5
---- ----------------------
(iii) Independent Accountants........................................................... 5
----- -----------------------
(iv) Financial Statements.............................................................. 5
---- --------------------
(v) No Material Adverse Change in Business............................................ 5
--- --------------------------------------
(vi) Good Standing of the Company...................................................... 5
---- ----------------------------
(vii) Good Standing of Subsidiaries..................................................... 6
----- -----------------------------
(viii) Capitalization.................................................................... 6
------ --------------
(ix) Authorization of Agreement........................................................ 6
---- --------------------------
(x) Authorization and Description of Securities....................................... 6
--- -------------------------------------------
(xi) Absence of Defaults and Conflicts................................................. 6
---- ---------------------------------
(xii) Absence of Labor Dispute.......................................................... 7
----- ------------------------
(xiii) Absence of Proceedings............................................................ 7
------ ----------------------
(xiv) Accuracy of Exhibits.............................................................. 8
----- --------------------
(xv) Possession of Intellectual Property............................................... 8
---- -----------------------------------
(xvi) Absence of Further Requirements................................................... 8
----- -------------------------------
(xvii) Possession of Licenses and Permits................................................ 8
------ ----------------------------------
(xviii) Title to Property................................................................. 8
------- -----------------
(xix) Environmental Laws................................................................ 9
----- ------------------
(xx) Investment Company Act............................................................ 10
---- ----------------------
(xxi) FDA and PTO Proceedings........................................................... 10
----- -----------------------
(b) Representations and Warranties by the Selling Shareholder.................................. 10
--- ---------------------------------------------------------
{/TABLE}
i
{PAGE}
{TABLE}
{S} {C}
(i) Accurate Disclosure............................................................... 10
--- -------------------
(ii) Authorization of Agreements....................................................... 10
---- ---------------------------
(iii) Security Entitlement.............................................................. 10
----- --------------------
(iv) Absence of Manipulation........................................................... 11
---- -----------------------
(v) Absence of Further Requirements................................................... 11
--- -------------------------------
(vi) No Association with NASD.......................................................... 11
---- ------------------------
(c) Officer's Certificates..................................................................... 11
--- ----------------------
SECTION 2. Sale and Delivery to Underwriters; Closing........................................................ 11
-----------------------------------------------------
(a) Initial Securities and Selling Shareholder Initial Securities.............................. 11
--- -------------------------------------------------------------
(b) Option Securities.......................................................................... 12
--- -----------------
(c) Payment.................................................................................... 12
--- -------
(d) Denominations; Registration................................................................ 13
--- ---------------------------
SECTION 3. Covenants of the Company.......................................................................... 13
----------------------------------
(a) Compliance with Securities Regulations and Commission Requests............................. 13
--- --------------------------------------------------------------
(b) Filing of Amendments....................................................................... 14
--- --------------------
(c) Delivery of Registration Statements........................................................ 14
--- -----------------------------------
(d) Delivery of Prospectuses................................................................... 14
--- ------------------------
(e) Continued Compliance with Securities Laws.................................................. 14
--- -----------------------------------------
(f) Blue Sky Qualifications.................................................................... 15
--- -----------------------
(g) Rule 158................................................................................... 15
--- --------
(h) Use of Proceeds............................................................................ 15
--- ---------------
(i) Listing.................................................................................... 15
--- -------
(j) Restriction on Sale of Securities.......................................................... 15
--- ---------------------------------
(k) Reporting Requirements..................................................................... 16
--- ----------------------
SECTION 4. Payment of Expenses............................................................................... 16
------------------------------
{/TABLE}
ii
{PAGE}
{TABLE}
{S} {C}
(a) Expenses................................................................................... 16
--- --------
(b) Expenses of the Selling Shareholder........................................................ 16
--- -----------------------------------
(c) Termination of Agreement................................................................... 16
--- ------------------------
(d) Allocation of Expenses..................................................................... 17
--- ----------------------
SECTION 5. Conditions of Underwriters' Obligations........................................................... 17
--------------------------------------------------
(a) Effectiveness of Registration Statement.................................................... 17
--- ---------------------------------------
(b) Opinion of Counsel for Company............................................................. 17
--- ------------------------------
(c) Opinion of Counsel to the Selling Shareholder.............................................. 17
--- ---------------------------------------------
(d) Opinion of Counsel for Underwriters........................................................ 18
--- -----------------------------------
(e) Officers' Certificate...................................................................... 18
--- ---------------------
(f) Certificate of Selling Shareholder......................................................... 18
--- ----------------------------------
(g) Accountants' Comfort Letter................................................................ 18
--- ---------------------------
(h) Bring-down Comfort Letter.................................................................. 19
--- -------------------------
(i) Approval of Listing........................................................................ 19
--- -------------------
(j) No Objection............................................................................... 19
--- ------------
(k) Lock-up Agreements......................................................................... 19
--- ------------------
(l) Conditions to Purchase of Option Securities................................................ 19
--- -------------------------------------------
(i) Officers' Certificate............................................................. 19
--- ---------------------
(ii) Opinion of Counsel for Company.................................................... 19
---- ------------------------------
(iii) Opinion of Counsel for Underwriters............................................... 19
----- -----------------------------------
(iv) Bring-down Comfort Letter......................................................... 19
---- -------------------------
(m) Additional Documents....................................................................... 20
--- --------------------
(n) Termination of Agreement................................................................... 20
--- ------------------------
SECTION 6. Indemnification................................................................................... 20
--------------------------
(a) Indemnification of Underwriters............................................................ 20
--- -------------------------------
{/TABLE}
iii
{PAGE}
{TABLE}
{S} {C}
(b) Indemnification of Company, Directors and Officers and Selling Shareholder................. 22
--- --------------------------------------------------------------------------
(c) Actions against Parties; Notification...................................................... 22
--- -------------------------------------
(d) Settlement without Consent if Failure to Reimburse......................................... 23
--- --------------------------------------------------
(e) Other Agreements with Respect to Indemnification........................................... 23
--- ------------------------------------------------
SECTION 7. Contribution...................................................................................... 23
-----------------------
SECTION 8. Representations, Warranties and Agreements to Survive Delivery.................................... 25
-------------------------------------------------------------------------
SECTION 9. Termination of Agreement.......................................................................... 25
-----------------------------------
(a) Termination; General....................................................................... 25
--- --------------------
(b) Liabilities................................................................................ 25
--- -----------
SECTION 10. Default by One or More of the Underwriters....................................................... 25
------------------------------------------------------
SECTION 11. Notices.......................................................................................... 26
-------------------
SECTION 12. Parties.......................................................................................... 26
-------------------
SECTION 13. GOVERNING LAW AND TIME........................................................................... 26
----------------------------------
SECTION 14. Effect of Headings............................................................................... 26
------------------------------
SCHEDULES
Schedule A - List of Underwriters Sch A-1
Schedule B - List of Sellers Sch B-1
Schedule C - Pricing Information Sch C-1
Schedule D - List of Persons and Entities Subject to Lock-up Sch D-1
EXHIBITS
Exhibit A-1 - Form of Opinion of General Counsel to Company A-1
Exhibit A-2 - Form of Opinion of Company's Counsel A-2
Exhibit B - Form of Opinion for Special Intellectual Property Counsel B-1
Exhibit C-1 - Form of Opinion of Counsel to Selling Shareholder C-1
Exhibit C-2 - Form of Opinion of General Counsel to Selling Shareholder C-2
Exhibit D - Form of Lock-up Letter D-1
Exhibit E - Information Provided by Selling Shareholder E-1
{/TABLE}
iv
{PAGE}
REGENERON PHARMACEUTICALS, INC.
(a New York corporation)
7,000,000 Shares of Common Stock
(Par Value $0.001 Per Share)
PURCHASE AGREEMENT
------------------
March 19, 2001
MERRILL LYNCH & CO.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
J.P. MORGAN SECURITIES INC.
ROBERTSON STEPHENS, INC.
as Representative of the several Underwriters
c/o Merrill Lynch & Co.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
North Tower
World Financial Center
New York, New York 10281
Ladies and Gentlemen:
Regeneron Pharmaceuticals, Inc., a New York corporation (the
"Company"), and Amgen Inc., a Delaware corporation (the "Selling Shareholder"),
------- -------------------
confirm their respective agreements with Merrill Lynch & Co., Merrill Lynch,
Pierce, Fenner & Smith Incorporated ("Merrill Lynch") and each of the other
-------------
Underwriters named in Schedule A hereto (collectively, the "Underwriters", which
------------
term shall also include any underwriter substituted as hereinafter provided in
Section 10 hereof), for whom Merrill Lynch is acting as representative (in such
capacity, the "Representative"), with respect to (i) the issue and sale by the
--------------
Company and the sale by the Selling Shareholder, acting severally and not
jointly, and the purchase by the Underwriters, acting severally and not jointly,
of the respective numbers of shares of Common Stock, par value $0.001 per share,
of the Company ("Common Stock") set forth in said Schedule A, and (ii) the grant
------------
by the Company to the Underwriters, acting severally and not jointly, of the
option described in Section 2(b) hereof to purchase all or any part of 1,050,000
additional shares of Common Stock to cover over-allotments, if any. The
aforesaid 7,000,000 shares of Common Stock (the "Initial Securities") to be
------------------
purchased by the Underwriters, of which 6,500,000 shall be issued and sold by
the Company, and of which 500,000 (the "Selling Shareholder Initial Securities")
--------------------------------------
shall be sold by the Selling Shareholder in accordance with Schedule B hereto,
and all or any part of the 1,050,000 shares of Common Stock subject to the
option described in Section 2(b) hereof (the "Option Securities") are
-----------------
hereinafter called, collectively, the "Securities". The Company acknowledges and
----------
agrees that the Selling Shareholder Initial Securities are "Registrable Shares"
as defined in the Class D Convertible
{PAGE}
Preferred Stock Purchase Agreement dated as of August 31, 1990 (the "Stock
Purchase Agreement") between the Company and the Selling Shareholder and the
Registration Rights Agreement dated as of April 15, 1996 (the "Registration
Rights Agreement") between the Company and the Selling Shareholder, that the
Selling Shareholder Initial Securities are being registered pursuant to Section
8.4 of the Stock Purchase Agreement and Section 4 of the Registration Rights
Agreement and that such Selling Shareholder is entitled to the benefits of the
Stock Purchase Agreement and the Registration Rights Agreement with respect to
such Selling Shareholder Initial Securities and the registration of the Selling
Shareholder Initial Securities.
The Company and the Selling Shareholder understand that the
Underwriters propose to make a public offering of the Securities as soon as the
Representative deems advisable after this Agreement has been executed and
delivered.
The Company has filed with the Securities and Exchange Commission (the
"Commission") a registration statement on Form S-3 (No. 333-54326) covering the
----------
registration of the Securities under the Securities Act of 1933, as amended (the
"1933 Act"), including the related preliminary prospectus or prospectuses.
--------
Promptly after execution and delivery of this Agreement, the Company will
prepare and file a prospectus in accordance with the provisions of Rule 430A
("Rule 430A") of the rules and regulations of the Commission under the 1933 Act
---------
(the "1933 Act Regulations") and paragraph (b) of Rule 424 ("Rule 424(b)") of
-------------------- -----------
the 1933 Act Regulations. The information included in such prospectus, that was
omitted from such registration statement at the time it became effective but
that is deemed to be part of such registration statement at the time it became
effective pursuant to paragraph (b) of Rule 430A is referred to as "Rule 430A
---------
Information". Each prospectus used before such registration statement became
-----------
effective, and any prospectus that omitted, as applicable, the Rule 430A
|
End of Preview |
Home Intelligence Services Subscriptions News About Us